Providence launches groundbreaking study to elevate real-world use of multi-cancer early detection

October 6, 2025 Sunjoy Prabakaran

Providence Genomics and Providence-Swedish Cancer Institute have launched the PREVAIL study, “Providence Evaluation of Annual Cancer Screenings” to understand the ways that individuals with a genetic predisposition to cancer access innovative screening tools and how access may impact their choices and care. These screening tools include access to specialized imaging and novel blood tests for cancer detection, including the Galleri test by GRAIL and others.  

 

The multi-year mixed methods study will follow enrolled participants for three years. Data collection includes participant surveys, interviews, and analysis of electronic health records. Recruitment for the study is ongoing in Providence Swedish, Washington, and California.

Find out more

Previous Article
Early Detection for More Patients: Prevention4ME expands and includes more data
Early Detection for More Patients: Prevention4ME expands and includes more data

Prevention4ME has identified more than 2600 patients at high risk for cancer who are now being screened dif...

Next Article
Comprehensive Genomic Profiling leads to better patient outcomes, a new joint study says
Comprehensive Genomic Profiling leads to better patient outcomes, a new joint study says

Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehe...